FindTrial
Sign In

KRP-108 long term study

Long term treatment study of KRP-108 for adult asthmatic patients

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221304
Enrollment
Unknown
Registered
2010-11-10
Start date
2010-11-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

investigational material(s) Generic name etc : KRP-108 (Fluticasone/Formoterol) INN of investigational material : Therapeutic category code : 229 Other agents affecting respiratory organs Dosage and

Sponsors

Kyorin Pharmaceutical Co.,LTD
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Patients treated with ICS(100-1000ug/day fluticasone propionate conversion) during 4 weeks before Visit1 -Patients whose FEV1.0 over 40% of predicted value. -Out patients And others.

Exclusion criteria

Exclusion criteria: -Patients who have previous/concurrent disease of malignant tumor -Patients who were hospitalization caused by exacerbation during 1 year before Vist1 -Patients who have lung infection currently -Patients treated with systemic steroids during 4 weeks before Visit1(except as-needed use less than defined dose) -Patients who have irreversible lung disease such as pulmonary fibrosis And others.

Design outcomes

Primary

MeasureTime frame
Safety and efficacy of KRP-108—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026